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Abstract
Purpose We present a case of a patient who developed
seizures shortly after initiating treatment with levofloxacin
and to discuss the potential drug-drug interactions related to
the inhibition of cytochrome P450 (CYP) 1A2 in this case,
as well as in other cases, of levofloxacin-induced seizures.
Methods Several biomedical databases were searched in-
cluding MEDLINE, Cochrane and Ovid. The main search
terms utilized were case report and levofloxacin. The search
was limited to studies published in English.
Results Six cases of levofloxacin-induced seizures have
been reported in the literature. Drug-drug interactions
related to the inhibition of CYP1A2 by levofloxacin are
likely involved in the clinical outcome of these cases.
Conclusions Clinicians are exhorted to pay close attention
when initiating levofloxacin therapy in patients taking
medications with epileptogenic properties that are CYP1A2
substrates.
Keywords Fluoroquinolones . Antibiotics . Side effects .
Antidepressants . Drug-drug interactions
Introduction
Levofloxacin is one of the new fluoroquinolones that has
been extensively prescribed based on its tolerability. A
recent study reported that levofloxacin is among the safest
medications in its class, with an adverse drug reaction rate
of only 2% [1]. Adverse effects involving the central
nervous system (CNS) are rare, and when present they
include headache, insomnia, agitation, and dizziness [2].
Even more infrequent, but of serious concern, is the
occasional appearance of convulsions [2]. There are only
five cases of levofloxacin-induced seizures published in
English in data bases such as MEDLINE, Ovid, and
Cochrane [2–4] (Table 1). Here, we present the case of a
patient who had no past history of convulsions and who
developed seizures shortly after initiating treatment with
levofloxacin. Potential drug-drug interactions taking place
in this patient as well as in previously published cases are
presented and their clinical implications are discussed.
Methods
Several biomedical databases were searched including
MEDLINE, Cochrane, and Ovid. The main search terms
utilized were case report and levofloxacin. The search was
limited to studies published in English. The causality
assessment of the current case was performed following
the Naranjo probability scale [5].
Case report
A 58-year old woman with no prior psychiatric history,
seizure episodes, or neurological problems was admitted to
the hospital with spiking fevers up to 39.1°C. She had a
history of chronic pancreatitis, breast cancer, and a total
abdominal hysterectomy for dysfunctional uterine bleeding.
On the 5th day of hospitalization, psychiatry was consulted
due to the patient’s lack of motivation and depressed mood.
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The patient acknowledged feeling depressed and anxious
and attributed this to the uncertain etiology of her
pancreatitis as well as the unclear origin of her fever. She
also reported poor sleep, poor appetite, low energy, and low
concentration. Due to concerns about her lack of appetite
and sleep, mirtazapine 7.5 mg orally at bedtime was started.
Her other medications at the time included metoclopramide
10 mg orally once a day, cefepime 1 g intravenous every
12 h, pantoprazole 40 mg orally once a day, and
acetaminophen 500 mg orally in case of fever or pain.
She tolerated this initial mirtazapine dose, which was
increased to 15 mg orally at bedtime on the 9th day of
admission. The following day, her temperature appeared
to be under control. She had a maximal temperature
of 37.8°C which contrasted with previous values of up
to 39.9°C. On her 10th day in the hospital, she developed
a rash to cefepime and the infectious diseases team
changed the medication to levofloxacin 500 mg orally once
a day.
The first dose of levofloxacin was given the afternoon of
the 11th day of hospitalization. That evening, the patient
lost consciousness and bowel control concomitantly. In the
early morning of the 12th day of admission, the patient’s
family reported seizure activity consisting of approximately
30 s of upper-extremity tonic-clonic contractions and loss
of bowel control. The patient could not remember these
events afterward. The second dose of levofloxacin was
given a few hours later, and shortly after, seizure activity
was noted by the registered nurse. In this episode, the
patient’s head turned to one side, she began foaming at the
mouth, and her eyes rolled back. She again showed tonic-
clonic contractions of her upper and lower extremities and
lost bowel control. Immediately after the seizure, she was
not oriented to place and could not provide her family
members’ names. Her medications at the time were
levofloxacin 500 mg/day orally, enoxaparin 40 mg/day
subcutaneous, metoclopramide 10 mg orally before each
meal, mirtazapine 15 mg/day orally, nystatin suspension
5 ml/day orally, pantoprazole 40 mg/day orally, and
acetaminophen 500 mg orally in case of fever or pain.
The patient was transferred to the intensive care unit for
workup of her seizures. Mirtazapine and levofloxacin were
discontinued, and the patient was started on fosphenytoin
for seizure control as well as aztreonam for her infection.
On the morning of the 12th day, her complete blood count
showed white blood cells 10.8×109/L with 86% neutro-
phils, hemoglobin 9.4 g/dl, hematocrit 30.2%, and platelets
553×109/L. A metabolic panel was within normal limits
except for sodium of 133 mEq/L and chloride of 96 mEq/L.
Her calcium was 6.8 mg/dl, although after correction with
an albumin of 2.9 g/dl, the calcium level was 7.68 mg/dl.
Moreover, her ionized calcium level taken the very next day
was within normal limits (1.15 mmol/L). Likewise, her
magnesium and phosphorus were normal. Her thyroid-
stimulating hormone level and computed tomography (CT)
of the head were unremarkable, and her abdominal CT
showed no changes and no abscesses. Her cerebrospinal
fluid (CSF), urine cultures, and cryptococcal antigen were
negative, and her CSF venereal disease research laboratory
test was nonreactive. In contrast, Klebsiella bacteremia was
Table 1 Case reports of levofloxacin-induced seizures
Reference Fluoroquinolone Antidepressant Other medications Time to seizure Clinical History
Kushner et al. [3] Levofloxacin
500 mg on day 1
and 250 mg
thereafter
Trazodone
(dose not
specified)
Levothyroxine, nabumetone,
risperidone, aspirin, enalapril,
isosorbide dinitrate
Day 3 of
levofloxacin
75 years; lower
limb ischemia
Kushner et al. [3] Levofloxacin
500 mg daily
Sertraline
50 mg daily
Nebulized albuterol, milk of
magnesia, cascara, alendronate,
haloperidol, sorbitol, donepezil,
benztropine, famotidine
Day 5 of
levofloxacin
74 years; bacterial
pneumonia with
pleural effusions
Christie et al. [2] Levofloxacin
500 mg daily
Paroxetine
5 mg daily
Prednisone, warfarin, folic acid,
levothyroxine
Approximately
7 h after first
dose of
levofloxacin
87 years;
unresponsiveness
Bird et al. [4] Levofloxacin
500 mg daily
Citalopram
40 mg daily
Donepezil, aspirin, doxazosin,
folate, gabapentin, divalproex
sodium, ranitidine
Approximately
after day 4 of
levofloxacin
75 years; seizure
disorder, renal
insufficiency and
Alzheimer’s disease
Bird et al. [4] Levofloxacin
500 mg daily
Not specified Donepezil Day 5 of levofloxacin 74 years; not specified
Current case Levofloxacin
500 mg daily
Mirtazapine
15 mg daily
Enoxaparin, metoclopramide,
nystatin suspension, pantoprazole
Approximately 5 h
after first dose of
levofloxacin
58 years; pancreatitis,
Klebsiella bacteremia
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found. No further seizure activity was reported, and she was
discharged home after 14 days in the hospital.
Discussion
Electrolyte abnormalities are well recognized causes of
convulsions. In this case, however, it is unlikely that this
patient’s serum sodium of 133 mEq/L had been the source of
convulsant activity, as patients in most instances remain
asymptomatic, even with sodium levels as low as 125 mEq/L.
Her calcium levels were also unlikely to be implicated,
because even though her serum calcium remained slightly low
after albumin correction, her ionized calcium was within
normal limits.
The epileptogenic nature of fever is also well recognized.
Nevertheless, in this case, it does not appear to be a
determinant factor considering this patient had body temper-
atures of up to 39.9°C without associated convulsions on
several occasions before treatment with levofloxacin was
initiated. Additionally, on the day of her first levofloxacin
dose, her body temperature was measured on four different
occasions and was never above 38.3°C.
In contrast to the lack of a direct association among
electrolyte abnormalities and fever with this patient’s con-
vulsions, there is a clear temporal relationship between the
initiation of levofloxacin and the appearance of seizures. In
fact, levofloxacin can readily cross the blood−brain barrier
[6], and thus its effects in the CNS can be rapidly observed.
In this case, seizures appeared only 5 h after the initial
levofloxacin dose. There is another report in the literature of
levofloxacin-induced seizures merely 7 h after the first dose
[2], whereas the other four cases so far reported resulted in
convulsions some days after starting this antibiotic (Table 1).
The mechanism of action by which fluoroquinolones
induce seizures remains poorly understood. It has been
related to the ability of these antimicrobials to either
antagonize the inhibitory effect of gamma-aminobutyric
acid (GABA) [6–8] or to its capacity to activate the N-
methyl-D-aspartate (NMDA) receptors [6, 9]. Most likely,
the epileptogenic properties arise from a combination of
both mechanisms.
Previous reports of fluoroquinolone-induced seizure
activity have suggested that the elderly and patients with
decreased renal function are at a higher risk [3]. In this
case, however, these factors do not apply. The patient was
not elderly and had an estimated creatinine clearance of
85 ml/mg [10]. Consequently, the dose of levofloxacin used
is within the range recommended by the current guidelines
[11]. The origin of seizures in this case was likely
levofloxacin epileptogenic properties. Nonetheless, a drug-
drug interaction cannot be totally excluded. According to the
Naranjo probability scale [5], levofloxacin was a “probable”
cause of seizures in this patient, whereas it is only “possible”
that a drug-drug interaction would have caused them.
Nonetheless, we believe it is worth reviewing potential
drug-drug interactions associated with fluoroquinolones.
When antibiotics within this family and nonsteroidal anti-
inflammatory drugs (NSAIDs) such as aspirin are combined,
the likelihood of seizures increases [12, 13], apparently due
to GABAB receptor antagonism [6, 7]. This drug-drug
interaction could have contributed to levofloxacin-induced
seizures in two previous cases (Table 1) [3, 4]. It is also
known that the epileptogenic risk increases when fluoroqui-
nolones are conjointly prescribed with theophylline [8, 14].
This is the result of fluoroquinolones eliciting CYP1A2
inhibition [14], which leads to a reduced theophylline
clearance and also because theophylline potentiates fluoro-
quinolone excitatory capacity [8]. Theophylline was not
involved, however, in any of the cases of levofloxacin-
induced seizures (Table 1), but it clearly exemplifies the
relevance of CYP1A2 inhibition by fluoroquinolones. A
drug relevant for the current case is metoclopramide.
Metoclopramide, a medication capable of inducing seizures
in overdose [15], is metabolized through CYP1A2 and
CYP2D6 [15]. Hence, levofloxacin inhibition of CYP1A2
could have contributed to the appearance of convulsions by
exposing our patient to high levels of metoclopramide. A
similar mechanism could have occurred with mirtazapine, an
antidepressant recently associated with seizures [16, 17] and
the metabolism of which depends on CYP1A2, 2D6, and
3A4 [15, 18]. Despite the three enzymes involved in its
clearance, the inhibition of only CYP1A4 can elicit more
than a two-fold increase of mirtazapine serum concentration
[18].
Interestingly, all the cases published in the English
literature of seizures related to levofloxacin have been in
patients taking some form of the new generation of
antidepressants [2–4] (Table 1). There is only one case in
which the patient’s medications and medical conditions
were not specified so that the link between antidepressants
and levofloxacin cannot be established [4] (Table 1).
Information about the effect of psychotropic medications
on seizure threshold is still not specific and is difficult to
translate into clinical practice. However, a consensus has
been reached on which of these drugs possess a higher risk
and which possess a lower risk in inducing seizure activity
[19]. The antidepressants used concomitantly in the
levofloxacin-induced seizure cases, including mirtazapine,
trazodone, paroxetine, and sertraline (Table 1), are among the
psychotropics that exhibit a low risk. Only mirtazapine is a
substrate of CYP1A2 [15]. Therefore, their role in the cases
of levofloxacin-induced seizures is yet to be established.
Another plausible explanation for the outcome of at least
some of the cases presented in Table 1 comes from
CYP1A2 substrates with no epileptogenic effects, such as
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nabumetone [20] and haloperidol [21], which could
augment the concentration of levofloxacin and consequent-
ly increase patients’ susceptibility to seizures. Nonetheless,
it has to be kept in mind that drug-drug interactions
originate at various pharmacodynamic and pharmacokinetic
levels and that drugs CYP affinities are seldom completely
CYP-specific, thus levofloxacin may have drug interactions
at the level of CYPs other than CYP1A2.
To conclude clinicians are advised to closely attend to
the possibility of seizures initiated by levofloxacin when
patients are taking other medications with epileptogenic
properties that are CYP1A2 substrates, such as mirtazapine,
metoclopramide, and theophylline.
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